UNSPSC 51181914: Lynestrenol or lynoestrenol

This classification denotes an a synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive which the molecular formula C20H28O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2Z8ALG4U5, chemically known as (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol but more commonly known as lynoestrenol, which bears US NIH Compound Identifier 5857. SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34.

UNSPSC 51181914 Lynestrenol or lynoestrenol, a Commodity code, covers the supply and distribution of this specific progestin pharmaceutical to state and local government healthcare facilities. In practice, this code encompasses manufacturers and suppliers providing generic pharmaceuticals, including hormonal contraceptives and related progestational agents, to state Medicaid programs, public health departments, correctional healthcare systems, and other government-operated medical facilities. The work involves manufacturing or sourcing the product to meet FDA compliance and Good Manufacturing Practices (cGMP) standards, coordinating with authorized pharmaceutical wholesalers, and maintaining pricing schedules compliant with state and local procurement requirements. Issuing bodies are typically state health departments and cooperative purchasing alliances coordinating multi-state pharmaceutical procurement; individual counties and municipalities rarely solicit this commodity directly, instead relying on state-level or regional cooperative agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and comply with FDA requirements, the Drug Supply Chain Security Act (DSCSA), and maintain commercial general liability insurance of $5 million per occurrence. The contract term is two years for new responders, with optional extensions at MMCAP's discretion, and awarded vendors will be effective July 1, 2026. Pricing is weighted at 75 percent of the evaluation, with secondary criteria including fixed pricing (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). No specific dollar values or budget ranges were disclosed in the solicitation materials, and the RFP does not indicate set-aside designations for disadvantaged enterprises.